B. Pre-sol_NOI.pdf

PRE-SOLICITATION NOTICE OF INTENT

NON-COMPETITIVE

INTRODUCTION

PURSUANT TO FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A PRE-

SOLICITATION NOTICE OF A PROPOSED CONTRACT TO ACTION.

THIS IS A PRE-SOLICITATION NON-COMPETITIVE NOTICE OF INTENT TO AWARD A CONTRACT

OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING

BRAND-NAME).

The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA) at the National Insitutes of Health (NIH) on behalf of the Divison of Pre-Clinical Innovation (DPI) within the National Center for Advancing Translatinal Sciences (NCATS) intends to negotiate and award a purchase order for the Celleca PLX Image Cytometer, PerkinElmer Health Sciences Inc., 68 Elm St, Hopkinton, Massachusetts 01748. This is a custom equipment system and PerkinElmer utilizes their factory-certified service engineers to furnish them. PerkinElmer Health Sciences Inc. does not certify or authorize any third parties to service their systems within North America and does not resell its parts and components to other vendors to use.

NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE

The intended procurement is classif ied under NAICS code 513210 – Sof tware Publishers Size Standard of $47.0 million

REGULATORY AUTHORITY

The resultant contract will include all applicable provisions and clauses of the Federal acquisition Requlation (FAR) currently in ef fect at https://www.acquisition.gov/

STATUTORY AUTHORITY

This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13— Simplif ied Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting f rom a single source.

DESCRIPTION OF REQUIREMENT

Project Description The Stem Cell Translational Laboratory (SCTL) within the National Center for Advancing Translational Sciences (NCATS) Division of Pre-Clinical Innovation dedicated to addressing scientific and technological challenges intends to estaqblish and move stem cell technologies forward through a more centralized ef fort.

The goal of the SCTL is to bring iPSC technology closer to clinical application, drug discovery and regenerative medicine. Through SCTL, NCATS will provide researchers across various disciplines and https://www.acquisition.gov/ organizations with the ability to establish collaborations to advance the translation of regenerative medicine applications. Through a multidisciplinary collaborative team approach, NCATS’ SCTL scientists aim to:

• Establish detailed quality control (QC) standards to def ine pluripotency and dif ferentiated cell types.

• Develop methods to assess variations in cultured cells derived f rom iPSCs.

• Develop standard methods to produce mature cells meeting the QC standards above.

• Discover, validate and disseminate small molecule reagents to replace expensive recombinant proteins, xenogenic material and undef ined media components in cell dif ferentiation protocols.

This instrument will be used upon routine iPSC maintenance and dif ferentiation culture to measure cell viability and immunophenotypes. This is a required instrument in cell culture labs as it provides precise information about the health, number of cells, and immunophenotypes of the cells being cultured by a biologist, while removing inter-operator variability that happens when counting manually. This equipment will be used routinely for internal and external collaborations. It will help NCATS to perform experiments in a steady and fast-paced manner.

Purpose and Objectives The Stem Cell Translation Laboratory (SCTL) within the National Center for Advancing Translational Sciences (NCATS) Division of Pre-Clinical Innovation (DPI) dedicated to addressing scientif ic and technological challenges, specifically, aims to bring iPSC technology closer to clinical application, drug discovery and regenerative medicine application.This project will require the Celleca PLX Image Cytomer

Delivery Date 30 Days af ter receipt of order.

CLOSING STATEMENT

This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice.

Responses to this Notice must include clear and convincing evidence of the offeror’s capability of fulfilling the requirement utilizing OEM-certif ied service engineers, access to knowledge of and proprietary sof tware for these customized systems, and ability to provide OEM parts and components.

In addition the Unique Entity Identif ier (UEI), the Taxpayer Identif ication Number (TIN), and the certif ication of business size must be included in the response. All of ferors must have an active registration in the System for Award Management (SAM) www.sam.gov.

A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.

All responses must be received by 12:00 PM EDT August 4, 2023. Responses must be emailed to the Contracting Specialist at chandani.hangilipola@nih.gov and reference the Notice ID 75N95023Q00518.

http://www.sam.gov/ mailto:chandani.hangilipola@nih.gov

“All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.”